Ocugen to Showcase Modifier Gene Therapy Platform at Key May Conferences
Event summary
- Ocugen will present its modifier gene therapy platform at two conferences in May 2026.
- Presentations scheduled for May 14 at Retina World Congress and May 26 at Stifel Virtual Ophthalmology Forum.
- Webcast of Stifel presentation available on Ocugen’s investor relations page.
- Company focuses on inherited retinal diseases and blindness diseases, including retinitis pigmentosa and Stargardt disease.
The big picture
Ocugen’s participation in high-profile conferences underscores its push to validate its modifier gene therapy approach, which targets complex diseases like retinitis pigmentosa and Stargardt disease. The biotech sector is increasingly focused on gene-agnostic therapies, and Ocugen’s ability to present compelling data could influence its standing among investors and competitors. The strategic focus on inherited retinal diseases positions Ocugen in a niche but growing segment of the ophthalmology market.
What we're watching
- Clinical Progress
- How Ocugen’s presentation data will impact investor confidence in its modifier gene therapy platform.
- Market Positioning
- Whether Ocugen can differentiate itself in the competitive gene therapy space.
- Regulatory Pathway
- The pace at which Ocugen advances its pipeline through clinical trials and potential regulatory filings.
Related topics